用于治疗慢性移植物抗宿主病的抗体

By using eklimab to block the CSF-1R receptor, the problems of toxicity and drug resistance in the treatment of chronic graft-versus-host disease have been solved, achieving effective treatment of chronic graft-versus-host disease and improving patients' quality of life.

CN122399012APending Publication Date: 2026-07-17SEDAX PHARM CO LTD
View PDF 14 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SEDAX PHARM CO LTD
Filing Date
2020-12-09
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Existing treatments for chronic graft-versus-host disease (cGVHD) have significant toxicity and drug resistance issues, and lack effective treatment options, impacting patients' long-term survival outcomes and quality of life.

Method used

Axatilimab, a high-affinity humanized IgG4 monoclonal antibody, is used to affect the migration, proliferation, and survival of monocytes by blocking the CSF-1R receptor and inhibiting its ligands CSF-1 and IL-34, thereby reducing the number of circulating monocytes.

Benefits of technology

It effectively alleviates the symptoms of chronic graft-versus-host disease, reduces circulating monocyte levels, decreases inflammatory responses, improves organ system symptoms, and enhances the quality of life for patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122399012A_ABST
    Figure CN122399012A_ABST
Patent Text Reader

Abstract

本发明涉及治疗硬化病况的方法，更具体地涉及用特定剂量的抗CSF‑1R抗体特别是艾克利单抗治疗慢性移植物抗宿主病的方法。
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Humanized immunoglobulins

    US5585089A

  • Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

    US8206715B2

  • Humanised antibodies

    WO1991009967A1

  • Photographic processing apparatus

    WO1992022853A1

  • Adjuvant for transcutaneous immunization

    WO1998020734A1